GSA Capital Partners LLP Cuts Holdings in Tarsus Pharmaceuticals, Inc. $TARS

GSA Capital Partners LLP lowered its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 41.4% during the third quarter, Holdings Channel.com reports. The fund owned 12,684 shares of the company’s stock after selling 8,944 shares during the quarter. GSA Capital Partners LLP’s holdings in Tarsus Pharmaceuticals were worth $754,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Jennison Associates LLC raised its holdings in shares of Tarsus Pharmaceuticals by 5.5% in the 3rd quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock worth $154,790,000 after purchasing an additional 136,582 shares during the period. Assenagon Asset Management S.A. raised its holdings in Tarsus Pharmaceuticals by 25.1% in the third quarter. Assenagon Asset Management S.A. now owns 1,247,954 shares of the company’s stock valued at $74,166,000 after buying an additional 250,367 shares during the period. Geode Capital Management LLC lifted its position in Tarsus Pharmaceuticals by 8.0% during the second quarter. Geode Capital Management LLC now owns 934,420 shares of the company’s stock valued at $37,859,000 after buying an additional 68,986 shares in the last quarter. Invesco Ltd. lifted its position in Tarsus Pharmaceuticals by 12.3% during the second quarter. Invesco Ltd. now owns 928,501 shares of the company’s stock valued at $37,614,000 after buying an additional 101,978 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its stake in Tarsus Pharmaceuticals by 6.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 543,000 shares of the company’s stock worth $21,997,000 after buying an additional 33,000 shares during the period. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 7,397 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total transaction of $592,499.70. Following the completion of the sale, the insider owned 38,958 shares in the company, valued at $3,120,535.80. This trade represents a 15.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total value of $495,060.00. Following the sale, the chief executive officer owned 857,991 shares in the company, valued at $70,792,837.41. This represents a 0.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 8.97% of the company’s stock.

Tarsus Pharmaceuticals Stock Up 1.6%

Shares of Tarsus Pharmaceuticals stock opened at $66.61 on Friday. The business has a 50-day moving average of $72.54 and a 200-day moving average of $67.82. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.29 and a quick ratio of 4.25. The company has a market capitalization of $2.83 billion, a PE ratio of -32.98, a P/E/G ratio of 0.96 and a beta of 0.57. Tarsus Pharmaceuticals, Inc. has a 1-year low of $38.51 and a 1-year high of $85.25.

Analyst Ratings Changes

TARS has been the topic of a number of research reports. Wall Street Zen raised shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. The Goldman Sachs Group reissued a “neutral” rating and issued a $68.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Guggenheim upped their target price on Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Zacks Research upgraded Tarsus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 23rd. Finally, Barclays assumed coverage on Tarsus Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $100.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Tarsus Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $82.29.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.